NASDAQ:STML - Stemline Therapeutics Stock Price, Forecast & News

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

Stemline Therapeutics Inc (NASDAQ:STML) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.08. The biopharmaceutical company earned $13.33 million during the quarter, compared to analyst estimates of $13.40 million. View Stemline Therapeutics' Earnings History.

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Stemline Therapeutics.

Stemline Therapeutics issued an update on its FY 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $43.2-43.2 million, compared to the consensus revenue estimate of $46.44 million.

7 analysts have issued twelve-month price objectives for Stemline Therapeutics' stock. Their forecasts range from $14.00 to $33.00. On average, they expect Stemline Therapeutics' stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 212.5% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.

News headlines about STML stock have been trending very negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stemline Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Stemline Therapeutics.

Some companies that are related to Stemline Therapeutics include IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Endonovo Therapeutics (ENDV), NextCure (NXTC), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Opko Health (OPK), Akebia Therapeutics (AKBA) and Enanta Pharmaceuticals (ENTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Exelixis (EXEL), Viking Therapeutics (VKTX), ZIOPHARM Oncology (ZIOP), Gilead Sciences (GILD), Fate Therapeutics (FATE), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Karyopharm Therapeutics (KPTI) and Opko Health (OPK).

Stemline Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Farallon Capital Management LLC (4.69%), State Street Corp (4.31%), Goldman Sachs Group Inc. (2.70%), Sectoral Asset Management Inc (2.04%), FMR LLC (1.76%) and Rhenman & Partners Asset Management AB (1.52%). Company insiders that own Stemline Therapeutics stock include Alan S Forman, David Gionco, Ivan Bergstein, Kenneth Hoberman and Robert Francomano. View Institutional Ownership Trends for Stemline Therapeutics.

STML stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, UBS Group AG, Citigroup Inc., Rafferty Asset Management LLC, Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund and Cubist Systematic Strategies LLC. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein, Kenneth Hoberman and Robert Francomano. View Insider Buying and Selling for Stemline Therapeutics.

STML stock was bought by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Rhenman & Partners Asset Management AB, FMR LLC, State Street Corp, Empire Life Investments Inc., Farallon Capital Management LLC, Credit Suisse AG and California Public Employees Retirement System. View Insider Buying and Selling for Stemline Therapeutics.

Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STML stock can currently be purchased for approximately $6.88.

Stemline Therapeutics has a market capitalization of $344.89 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-85,020,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.View Additional Information About Stemline Therapeutics.

The official website for Stemline Therapeutics is http://www.stemline.com/.

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]